(Press-News.org) NEW YORK, NY (May 23) – The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus. The Lupus Landmark Study, the largest study of its kind in lupus, will prospectively recruit and longitudinally follow 3,500 adults diagnosed with systemic lupus erythematosus (SLE). The Lupus Landmark Study is a key component of the Lupus Nexus, a state-of-the-art, patient-centric, collaborative research resource.
The aim of the Lupus Nexus is to transform lupus research and drug development through unprecedented information exchange capabilities. The platform will provide a collaborative solution that is inclusive of diverse patient populations disproportionally affected by lupus. The Lupus Nexus will be a source of highly curated clinical data, patient reported data, biological samples, and raw analyzed data to catalyze global collaboration, innovation, and precision medicine approaches in lupus.
“We are thrilled to launch the Lupus Landmark Study as the first phase of the Lupus Nexus,” said Teodora Staeva, PhD, VP and Chief Scientific Officer of the Lupus Research Alliance. “This is a significant milestone for the lupus community and an opportunity to enable major breakthroughs in our understanding and treatment of lupus. We are immensely grateful to all our collaborative partners who have brought us to this stage, including people with lupus, clinicians, researchers, industry, government, and non-profit entities.”
People with lupus have played a key role in the development of the Lupus Nexus and will continue to be at the core of this effort through their participation in the Lupus Landmark Study. Their engagement will generate the data needed to drive patient-centric treatments as well as allow participants greater visibility into their own personal health data.
“Not only is it important to understand lupus from the vantage point of each person living with this disease, but it’s important that researchers and patients have a voice in these important initiatives,” said Ruth Wilson, member of the Lupus Nexus Steering Committee and the Executive Committee of LRA’s Young Leaders Board. “It’s exciting to see this study come to life and an honor to provide my perspective and feedback as both a researcher and lupus patient advocate.”
The Lupus Nexus will support both discovery and clinical development research. Scientists will correlate deidentified data from the Landmark Study with analyzed biosample data to identify or validate drug targets, biomarkers, and hypothesis, with the goal of ultimately understanding disease heterogeneity and developing more effective diagnostic, prognostic, and treatment approaches for lupus.
“A critical part of unlocking new insights into this complex disease is greater collaboration and data sharing among the global lupus research community,” said S. Sam Lim, MD, MPH, lead investigator of the Lupus Landmark Study, and Professor of Medicine, Emory University and Chief of Rheumatology at Grady Memorial Hospital. “My hope is that with the Lupus Landmark Study and the Lupus Nexus, we’ll not only have better data, but we’ll be able to better collaborate to find more treatments that will enable more personalized care for people with lupus.”
In addition to the Lupus Landmark Study, other key structural components of the Lupus Nexus include its clinical coordinating center, biorepository, and data/knowledge portal. The Lupus Research Alliance has engaged Embleema and Azenta Life Sciences as the clinical coordinating center and biorepository, respectively. DxTerity Diagnostics, Inc. will conduct biomarker analysis using their proprietary DxCollection MicroCollection Device and Modular Immune Profile (MIP) platform.
The Lupus Landmark Study and Lupus Nexus are part of the Lupus Research Alliance’s bold Strategic Plan for Research that addresses critical needs for advancing research, including defining lupus heterogeneity, stratifying patients by active disease mechanism, and establishing motivated and collaborative global research/technology teams.
The Lupus Landmark Study will begin enrolling in select academic medical centers in the Lupus Therapeutics Lupus Clinical Investigators Network (LuCIN) later this year with expanded roll-out in 2024. To find out more information about the Lupus Landmark Study, please contact the Lupus Nexus team at LupusNexus@lupusresearch.org.
Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. Nine out of 10 people with lupus are women; lupus most often strikes during the childbearing years of ages 15 to 45. Black/African American, Hispanic/Latino, Asian, and Native American populations are two to three times at greater risk than Caucasians. In lupus, the immune system, which is designed to protect against infection, creates antibodies that can attack any part of the body including the kidneys, brain, heart, lungs, blood, skin, and joints.
About the Lupus Research Alliance
The Lupus Research Alliance (LRA) is the largest non-governmental, non-profit funder of lupus research worldwide. The organization aims to transform treatment by funding the most innovative lupus research, fostering diverse scientific talent, and driving discovery toward better diagnostics, improved treatments and ultimately a cure for lupus. Because the LRA board of directors funds all administrative and fundraising costs, 100 percent of all donations support lupus research programs. Visit LupusResearch.org to learn more, and follow us on LinkedIn, Twitter, Facebook, and Instagram.
About Lupus Therapeutics
Lupus Therapeutics, an affiliate of the Lupus Research Alliance, aims to accelerate drug discovery and diagnostic innovation for all patients living with lupus. Lupus Therapeutics collaborates with biotechnology and pharmaceutical partners through its unprecedented Lupus Clinical Investigators Network (LuCIN) to drive rapid and meaningful progress in the treatment of lupus patients. The organization aims to place the patient voice and community stakeholders at the center of the clinical research process with the most innovative and renowned experts throughout North America. Visit LupusTherapeutics.org to learn more.
Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics launch the Lupus Landmark Study to accelerate personalized treatments in lupus
ELSE PRESS RELEASES FROM THIS DATE:
The severity of sleep apnea may be underestimated in Black patients
Session: C110, Advanced Signal Analysis: New Diagnostics and Physiologic Insights for SDB (sleep-disordered breathing) Date and Time: 2:15 p.m. ET, Tuesday, May 23, 2023 Location: WEWCC, Room 144 A-C (Street Level) ATS 2023, Washington, DC – Obstructive sleep apnea (OSA) tests may underestimate the severity of OSA in Black patients, according to research published at the ATS 2023 International Conference. Recent research with ICU patients during the COVID-19 pandemic showed that pulse oximeters—clip-like devices that are attached to a fingertip to measure blood oxygen ...
Strategic city planning can help reduce urban heat island effect
UNIVERSITY PARK, Pa. — The tendency of cities to trap heat — a phenomenon called the “urban heat island,” often referred to as the UHI effect — can lead to dangerous temperatures in the summer months, but new Penn State research suggests that certain urban factors can reduce this effect. The study found that trees had a cooling effect on outdoor air temperature, mean radiant temperature and predicted mean vote index, a measurement designed to evaluate thermal comfort levels. Additionally, the researchers determined that higher building-height-to-street-width ratios — when taller ...
The aging mouse prostate: kinetics of lymphocyte infiltration
“This dataset presents the most comprehensive profiling of the aging adult mouse prostate immune profile to date.” BUFFALO, NY- May 23, 2023 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 9, entitled, “Highly multiplexed immune profiling throughout adulthood reveals kinetics of lymphocyte infiltration in the aging mouse prostate.” Aging is a significant risk factor for disease in several tissues, including the prostate. Defining the kinetics ...
Organizations must go beyond medical views on menopause to support women’s professional aspirations - study
Organisations must enable mid-life women to thrive in the workplace by taking inspiration from societies such as China and Japan to encourage positive conversations around the impact of menopause, a new study reveals. But as they support older women in pursuing their ambitions and accessing career opportunities, organisations must ensure they do not hinder career progression through overlooked promotions, undervalued work, and lost opportunities. In Western countries, the menopause is traditionally viewed as a managed medical condition that creates physiological challenges which women must overcome if they are to function as effectively in the workplace ...
Insomnia drug class may not influence death and exacerbation risks among patients with COPD
Session: C98, Risky Business: Predicting Consequences of OSA Date and Time: 2:51 p.m. ET, Tuesday, May 23, 2023 Location: Marriott Marquis Washington, Independence Ballroom, Salons E-H (Level M4) ATS 2023, Washington, DC – Chronic obstructive pulmonary disease patients newly prescribed non-benzodiazepine benzodiazepine receptor agonists (NBZRAs) such as zolpidem (Ambien, Intermezzo and other brands), a class of hypnotic drugs prescribed for insomnia, did not have an increased risk of exacerbations requiring hospitalizations or of death than those prescribed ...
Researchers treat depression by reversing brain signals traveling the wrong way
Powerful magnetic pulses applied to the scalp to stimulate the brain can bring fast relief to many severely depressed patients for whom standard treatments have failed. Yet it’s been a mystery exactly how transcranial magnetic stimulation, as the treatment is known, changes the brain to dissipate depression. Now, research led by Stanford Medicine scientists has found that the treatment works by reversing the direction of abnormal brain signals. The findings also suggest that backward streams of neural activity between key areas of the brain could be used as a biomarker to help diagnose depression. “The leading ...
Strategic habitat restoration can generate a win-win for forests and farmers
Carefully planned restoration of agricultural coffee landscapes can increase both farmers’ profit and forest cover over a 40-year period, according to a study publishing May 23rd in the open access journal PLOS Biology by Dr. Sofía López-Cubillos at the University of Queensland in Australia, and colleagues. Restoring patches of natural vegetation in agricultural land presents a trade-off for farmers: while the lost cropland can reduce profitability, increases in ecosystem services like pollination can improve crop yield. To investigate how conservation priorities can be balanced with economic needs, researchers developed a novel planning framework to model the ...
Oxygen restriction helps fast-aging mice live longer
For the first time, researchers have shown that reduced oxygen intake, or “oxygen restriction”, is associated with longer lifespan in lab mice, highlighting its anti-aging potential. Robert Rogers of Massachusetts General Hospital in Boston, US, and colleagues present these findings in a study publishing May 23rd in the open access journal PLOS Biology. Research efforts to extend healthy lifespan have identified a number of chemical compounds and other interventions that show promising effects in mammalian lab animals— ...
How the February 2023 Türkiye earthquakes ruptured and produced damaging shaking
Three studies now published in the open-access journal The Seismic Record offer an initial look at the February 6, 2023 earthquakes in south-central Türkiye and northwestern Syria, including how, where, and how fast the earthquakes ruptured and how they combined as a “devastating doublet” to produce damaging ground shaking. The two earthquakes, a magnitude 7.8 followed approximately nine hours later by a magnitude 7.6, took place at the tectonically active and complex junction between the Anatolian, Arabian, and ...
Rural patients with diabetes experience worse health outcomes than urban patients
Rural Patients With Diabetes Experience Worse Health Outcomes Than Urban Patients Mayo Clinic researchers conducted a study within their health care system to identify factors associated with quality of care among rural and urban patients with diabetes. The study evaluated patient attainment of a five-component diabetic care metric, known as the D5 metric. This metric includes no tobacco use, hemoglobin A1C <8%, blood pressure <140/90, statin use, and aspirin use. Researchers considered age, sex, race, Adjusted Clinical Group score (a series of mutually exclusive, health status categories defined by morbidity, age, and sex), insurance type, primary care clinician type, ...